Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma

We have reported that IgG antibody responses following two mRNA COVID-19 vaccinations are impaired among patients with multiple myeloma (MM). In the current study, sixty-seven patients with MM were tested for anti-spike IgG antibodies 0–60 days prior to their first vaccination, 14–28 days following...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldwater, Marissa-Skye, Stampfer, Samuel D., Sean Regidor, Bernard, Bujarski, Sean, Jew, Scott, Chen, Haiming, Xu, Ning, Kim, Clara, Kim, Susanna, Berenson, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of British Infection Association. 2023
Materias:
Clinical Audits/Service improvements
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744558/
https://www.ncbi.nlm.nih.gov/pubmed/36530752
http://dx.doi.org/10.1016/j.clinpr.2022.100214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744558/
https://www.ncbi.nlm.nih.gov/pubmed/36530752
http://dx.doi.org/10.1016/j.clinpr.2022.100214

Ejemplares similares